Solventum Q2 sales up 3.9% to $2.2B; raises FY organic growth & EPS guidance

Solventum Corp

2025-Q2 EPS reported $1.30 revenue$4,231,000,000

GAAP diluted EPS $0.51; adjusted diluted EPS $1.69 (+8.3% YoY).
Organic sales +2.8%; all segments positive, led by MedSurg and HIS.
Adjusted operating margin expanded 120 bps to 21.9%.
FY 2025 organic sales guidance raised to +2.0%-3.0%; EPS raised to $5.80-$5.95.
Operating cash flow $169M; free cash flow $59M in Q2.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.